Rapid Micro Biosystems Inc (RPID)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $32.65M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rapid Micro Biosystems Inc (RPID) Earnings: Report Dates and Results
Rapid Micro Biosystems (RPID) is expected to report earnings on Mar 10, 2027. In the quarter ended Jun 30, 2026, Rapid Micro Biosystems reported EPS of -$0.27, below the -$0.26 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RPID has an expected report date of Mar 10, 2027.
RPID Earnings Call
The latest RPID earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 20 quarters below that had an estimate, RPID beat 4, missed 14 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $8.05M, up 10.9% from $7.26M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.27 | -$0.26 | -$0.26 - -$0.23 | -3.85% | Miss | N/A | 3 | N/A | Aug 7, 2026 | $8.05M |
| Mar 31, 2026 | -$0.31 | -$0.21 | -$0.28 - -$0.21 | -47.62% | Miss | N/A | 3 | 0 up, 0 down | May 13, 2026 | $8.00M |
| Dec 31, 2025 | -$0.28 | -$0.23 | -$0.24 - -$0.22 | -21.74% | Miss | N/A | 3 | 0 up, 0 down | Mar 12, 2026 | $11.28M |
| Sep 30, 2025 | -$0.26 | -$0.24 | -$0.27 - -$0.22 | -8.33% | Miss | N/A | 4 | 0 up, 2 down | Nov 7, 2025 | $7.84M |
| Jun 30, 2025 | -$0.27 | -$0.25 | -$0.27 - -$0.24 | -8.00% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2025 | $7.26M |
| Mar 31, 2025 | -$0.26 | -$0.27 | -$0.27 - -$0.27 | +3.70% | Beat | N/A | 1 | 0 up, 0 down | May 9, 2025 | $7.21M |
| Dec 31, 2024 | -$0.22 | -$0.21 | -$0.24 - -$0.21 | -4.76% | Miss | N/A | 2 | 1 up, 1 down | Feb 28, 2025 | $8.22M |
| Sep 30, 2024 | -$0.26 | -$0.25 | -$0.26 - -$0.25 | -4.00% | Miss | N/A | 2 | 0 up, 0 down | Nov 1, 2024 | $7.60M |
| Jun 30, 2024 | -$0.29 | -$0.28 | -$0.28 - -$0.27 | -3.57% | Miss | N/A | 3 | 0 up, 0 down | Aug 2, 2024 | $6.62M |
| Mar 31, 2024 | -$0.31 | -$0.29 | -$0.30 - -$0.28 | -6.90% | Miss | N/A | 3 | 0 up, 0 down | May 3, 2024 | $5.61M |
| Dec 31, 2023 | -$0.26 | -$0.30 | -$0.31 - -$0.29 | +13.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 1, 2024 | $6.34M |
| Sep 30, 2023 | -$0.31 | -$0.28 | -$0.32 - -$0.28 | -10.71% | Miss | N/A | 3 | 0 up, 0 down | Nov 3, 2023 | $6.14M |
| Jun 30, 2023 | -$0.33 | -$0.33 | N/A | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 4, 2023 | $5.00M |
| Mar 31, 2023 | -$0.32 | -$0.36 | -$0.39 - -$0.34 | +11.11% | Beat | N/A | 4 | 0 up, 0 down | May 5, 2023 | $5.04M |
| Dec 31, 2022 | -$0.39 | -$0.36 | -$0.39 - -$0.33 | -8.33% | Miss | N/A | 3 | 0 up, 0 down | Mar 3, 2023 | $4.37M |
| Sep 30, 2022 | -$0.38 | -$0.36 | -$0.38 - -$0.36 | -5.56% | Miss | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | $4.74M |
| Jun 30, 2022 | -$0.31 | -$0.35 | N/A | +11.43% | Beat | N/A | N/A | 0 up, 0 down | Aug 12, 2022 | $3.86M |
| Mar 31, 2022 | -$0.35 | -$0.32 | -$0.38 - -$0.27 | -9.38% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2022 | $4.16M |
| Dec 31, 2021 | -$0.35 | -$0.28 | -$0.34 - -$0.19 | -25.00% | Miss | N/A | 4 | N/A | Mar 4, 2022 | $5.21M |
| Sep 30, 2021 | -$0.39 | -$0.39 | -$0.43 - -$0.37 | 0.00% | In line | N/A | 3 | 1 up, 0 down | Nov 11, 2021 | $6.90M |
| Jun 30, 2021 | -$20.01 | -$0.40 | N/A | N/A | N/A | N/A | N/A | N/A | Jul 16, 2021 | $6.13M |
| Mar 31, 2021 | -$0.69 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 2, 2021 | $5.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.07, after -$1.08 the year before. It was -$21.44 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.07 | N/A |
| Dec 31, 2024 | -$1.08 | N/A |
| Dec 31, 2023 | -$1.22 | N/A |
| Dec 31, 2022 | -$1.43 | N/A |
| Dec 31, 2021 | -$21.44 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 6,300 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 6,295 | 8 | |
| 2026Q1 | Mar 31, 2026 | 4,753 | 8 | |
| 2025Q4 | Dec 31, 2025 | 5,278 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,987 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,263 | 8 | |
| 2025Q1 | Mar 31, 2025 | 3,575 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,307 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,522 | 6 |
2026Q2 Earnings Call
Opening remarks
Michael Beaulieu Investor Relations Good morning, and thank you for joining the Rapid Micro Biosystems Second Quarter Earnings Call. Joining me on the call are Rob Spignesi, President and Chief Executive Officer; and Sean Wirtjes, Chief Financial Officer. This morning, we issued a press release announcing our second quarter results. A copy of the release is available on the company's website at rapidmicrobio.com under Investors in the News and Events section. Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements, including, but not limited to, statements relating to Rapid Micro's financial condition, assumptions regarding future financial performance, anticipated future cash usage, statements relating to the company's term loan facility, guidance for 2026, including revenue, expenses, gross margin, system placements and validation activities, expectations for and planned activities related to Rapid Micro's business development and growth, including the expected benefits from our distribution and collaboration agreement with MilliporeSigma, customer interest and adoption of the Growth Direct System and the impact of the Growth Direct system on their businesses and operations and statements regarding the potential impact of general macroeconomic conditions on our business and that of our customers. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors, including our ability to meet publicly announced guidance, the impact of our existing and any future indebtedness on our ability to operate our business, our ability to achieve the milestones necessary to access any future tranches under our existing debt facility and to comply with all of its obligations thereunder, our ability to access additional capital, such as through the exercise of our recently issued warrants, our ability to deliver products to customers and recognize revenue and market and macroeconomic conditions. For a more detailed list and description of the risks and uncertainties associated with Rapid Micro's business, please refer to the Risk Factors section of our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as updated from time to time in subsequent filings with the SEC. We urge you to consider these factors, and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. Please note that today's remarks include certain non-GAAP financial measures.
Frequently Asked Questions About RPID
When is Rapid Micro Biosystems's next earnings date?
Rapid Micro Biosystems's next earnings report is expected for Mar 10, 2027.
Did RPID beat earnings estimates last quarter?
No. Rapid Micro Biosystems reported EPS of -$0.27 for the quarter ended Jun 30, 2026, below the -$0.26 estimate by 3.85%.
What EPS do analysts expect from RPID next quarter?
The consensus EPS estimate for Rapid Micro Biosystems for the quarter ending Dec 31, 2026 is -$0.16 from 5 analysts, with estimates from -$0.18 to -$0.14.
How often does RPID beat earnings estimates?
Rapid Micro Biosystems beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -11.82%.
RPID pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts